[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-cough\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-cough":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,76,104,125,154,186,211,236,256,279,302,326],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641451","remodelling-of-the-lower-airways-in-chronic-cough-100641451",false,"NCT07659860","Remodelling of the Lower Airways in Chronic Cough","Does Chronic Cough Lead to Injury and Remodelling of the Lower Airways?","Inclusion criteria for the study group:\n\n1. age between 18 and 75 years,\n2. chronic cough of at least one year duration, with no previous treatment (at least 2 previous unsuccessful attempts at pharmacological treatment of cough)\n3. negative history of smoking (at least 6 months of abstinence),\n4. negative history of treatment with angiotensin-converting enzyme inhibitors (ACEI),\n5. normal chest radiograph or with changes not relevant to cough formation,\n6. no respiratory tract infections in the past 6 weeks,\n7. written consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n1. patients less than 18 and more than 75 years of age,\n2. cough lasting less than 12 months,\n3. active smoking or abstinence period of less than 6 months,\n4. respiratory tract infection 6 weeks prior to inclusion or at the time of study conduct - retry inclusion after 6 weeks,\n5. cancer or interstitial lung disease,\n6. contraindications to functional testing, sputum induction or bronchoscopy","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The aim of the study is to assess if chronic cough leads to injury and remodelling of the airways. We plan to analyse bronchial injury and remodelling in patients with refractory chronic cough lasting longer than 12 month . Assessment of injury mediators will be performed in blood and bronchoalveolar lavage fluid. Remodelling features will be analysed based on chest CT scan and pathologic specimens. Injury of epithelium will be assessed in bronchial biopsy specimens. The relationship between the duration, severity of chronic cough, and bronchial inflammation, damage, remodelling will be analysed.",[25],"Chronic Cough",[27,28],"remodelling","chronic cough","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":33},"2022-10-01",{"date":37,"type":21},"2026-08-30",{"name":39,"class":40},"Medical University of Warsaw","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100639046","phase-3-finnish-childrens-protracted-cough-100639046","NCT07582549","Finnish Children´s Protracted Cough","A Randomized, Double-blinded Clinical Trial Comparing the Efficacy of Antibiotic or Inhaled Corticosteroid to Placebo in Children´s Protracted Cough","FINNCHICO","Inclusion Criteria:\n\n* Prolonged cough lasting continuously for more than 4 weeks\n* No chronic disease requiring continuous medication (i.e. a generally healthy child)\n* No previous physician-diagnosed condition associated with prolonged cough episodes\n* No physician-identified symptoms or findings suggestive of an underlying disease\n* No prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products (fluticasone or amoxicillin-clavulanic acid)\n* No simultaneous participation in another clinical drug trial\n* Parents\u002Fguardians have sufficient spoken and written Finnish language proficiency\n* Written, voluntary informed consent provided by a parent or legal guardian\n\nExclusion Criteria:\n\nChildren with symptoms or findings suggestive of an underlying cause of cough, including:\n\n* A previously physician-diagnosed disease associated with prolonged cough\n* Clinical examination or history at the study visit raising suspicion of a disease associated with prolonged cough (positive \"cough pointers\")\n* Abnormal lung function test\n* Abnormal chest X-ray (peribronchial markings are permitted)\n\nAdditional exclusion criteria:\n\n* Prior physician-diagnosed allergic reaction or other severe or life-threatening adverse reaction to the investigational medicinal products\n* Simultaneous participation in another clinical drug trial\n* Prolonged cough that has resolved spontaneously prior to the study visit","1 Year","6 Years",{"count":53,"type":21},100,"INTERVENTIONAL",[56],"PHASE3","Prolonged cough lasting more than four weeks is common in children, but the best treatment is often unclear when no underlying disease can be found. This study aims to find out whether commonly used treatments help children with prolonged cough more effectively than placebo.\n\nChildren who take part will first undergo standard medical examinations, including lung function tests and a chest X-ray, to look for the cause of the cough. If no specific cause is found, the child may enter the study.\n\nChildren with a dry cough will be randomly assigned to receive either an inhaled corticosteroid (fluticasone) or a placebo inhaler for two months. Children with a wet or productive cough will be randomly assigned to receive either an oral antibiotic (amoxicillin-clavulanic acid) or a placebo medicine for 14 days. Neither the families nor the researchers will know which treatment the child receives during the study.\n\nThe main goal is to determine whether these treatments significantly reduce or stop the cough compared with placebo. The results will help improve treatment recommendations for children with prolonged cough and avoid unnecessary medication use.\n\nParticipation is voluntary, and parents provide written informed consent for their child.",[25],[25,60,61,62,63,64,65],"Child","Fluticasone Propionate","Amoxicillin-Potassium Clavulanate Combination","Randomized Controlled Trial","Double-Blind Method","Phase III","2026-05-05",{"date":68,"type":33},"2026-05-13",{"date":70,"type":33},"2025-12-22",{"date":72,"type":21},"2027-12",{"name":74,"class":40},"Tampere University Hospital",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":54,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":75},"100636471","feasibility-acceptability-and-safety-trial-of-brief-breath-control-focused-acceptance-and-commitment-therapy-in-adults-with-chronic-cough-100636471","NCT07566117","Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in Adults With Chronic Cough","Identifying Predictors of Treatment Response to Pharmacologic and Nonpharmacologic Interventions in Cough Hypersensitivity Syndrome","FAST-COUGH","Inclusion Criteria:\n\n* Confirmed patient with UNC Health electronic medical record number (MRN) via medical chart review\n* 18-80 years of age via medical chart review\n* Completed outpatient clinical encounter within the prior 12 months with a provider in pulmonary medicine, gastroenterology, otolaryngology, and\u002For allergy at UNC Health via medical chart review, with documentation that chronic cough (lasting 8 weeks or longer) was listed as one of the reasons for the visit, with terminology such as, but not limited to chronic, ongoing, recurrent, persistent, lingering, refractory, longstanding, constant, continual, continuous, prolonged, intermittent, frequent, repetitive, unresolved, non-resolving, habitual, troublesome, bothersome, unmanaged, unexplained, idiopathic, progressive, worsening, treatment-resistant, and\u002For intractable\n* Documented interpretation by provider of normal chest imaging, defined as a chest radiograph (X-ray) or computed tomography (CT) scan of the chest without clinically significant abnormalities contributing to chronic cough, within the prior 12 months obtained as part of the evaluation for chronic cough via medical chart review\n* Documented judgment of provider within the prior 12 months that chronic cough was not primarily attributable to untreated or inadequately treated pulmonary, gastroesophageal, or sinonasal condition(s) via medical chart review\n* Chronic cough of at least moderate severity (i.e., moderate, severe, very severe) via self-report using a screening questionnaire\n* Score ≤ 14 on the Patient Health Questionnaire-9 (PHQ-9), indicating no greater than moderate depressive symptom severity (maximum score: 27), via self-report using a screening questionnaire\n* Score of ≤ 14 on the Generalized Anxiety Disorder-7 (GAD-7), indicating no greater than moderate generalized anxiety symptoms (maximum score: 21), via self-report using a screening questionnaire\n* Score of ≤ 10 on the Distress Questionnaire-5 (DQ5), indicating no elevated psychological distress (maximum score: 25), via self-report using a screening questionnaire\n* Agree to participate in a program to learn new ways to manage chronic cough for 4 weeks via self-report using a screening questionnaire\n* Able to participate in study activities with a facilitator scheduled during standard weekday business hours via self-report using a screening questionnaire\n* Access to reliable internet connection and device capable of videoconferencing (e.g., computer, tablet, smartphone) via self-report using a screening questionnaire\n\nExclusion Criteria:\n\n* Current smoking status via medical chart review\n* Current use of angiotensin-converting enzyme (ACE) inhibitor medication(s) via medical chart review, including Benazepril\u002Fbrand name: Lotensin; Captopril\u002Fbrand name: Capoten; Enalapril\u002Fbrand name: Vasotec; Fosinopril\u002Fbrand name: Monopril; Lisinopril\u002Fbrand name: Prinivil, Zestril; Moexipril\u002Fbrand name: Univasc; Perindopril\u002Fbrand name: Aceon; Quinapril\u002Fbrand name: Accupril; Ramipril\u002Fbrand name: Altace; and\u002For Trandolapril\u002Fbrand name: Mavik\n* Unable to read, understand, and speak English without an interpreter via medical chart review\n* Documented cognitive, intellectual, developmental, or neurological conditions that could interfere with reliable self-report, comprehension, or completion of study procedures via medical chart review","80 Years",{"count":86,"type":21},30,[88],"NA","This study is a prospective, single-center, single-arm pilot trial. The primary research question is whether brief, breath control-focused Acceptance and Commitment Therapy (ACT) is feasible, acceptable, and safe in adults with chronic cough.",[25],[28,92,93],"cough","cough hypersensitivity syndrome","NOT_YET_RECRUITING","2026-05-04",{"date":97,"type":33},"2026-05-06",{"date":99,"type":21},"2026-08-01",{"date":101,"type":21},"2029-06-30",{"name":103,"class":40},"University of North Carolina, Chapel Hill",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":54,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":75},"100630509","efficacy-of-behavioral-therapy-for-chronic-refractory-cough-100630509","NCT07488598","Efficacy of Behavioral Therapy for Chronic Refractory Cough","Efficacy of Behavioral Therapy for Chronic Refractory Cough in Patients With Laryngeal Hyperresponsiveness","Inclusion Criteria:\n\n* Eligible participants are adults aged ≥18 years i.e. normal chest radiograph.\n* participants with chronic cough persisting for more than eight weeks that is refractory to standard medical treatment for common causes of chronic cough, including asthma, gastroesophageal reflux disease .\n* Participants are required to exhibit clinical features suggestive of laryngeal hyperresponsiveness, such as cough triggered by phonation, laughter, cold air, or irritant exposure, with associated laryngeal symptoms including throat irritation, dysphonia, or frequent throat clearing.\n\nExclusion Criteria:\n\n* Patients are excluded if they are current smokers or had ceased smoking within six months\n* patients have evidence of active pulmonary or cardiac disease, recent respiratory tract infection, recent angiotensin-converting enzyme inhibitor use.\n* significant structural laryngeal pathology, neurological disorders affecting cough reflex control, or inability to comply with study procedures.\n* Head \\&neck pathology e.g sinusitis, glottal insufficiency or primary muscle tension dysphonia","50 Years",{"count":86,"type":21},[88],"Chronic cough is defined as cough persisting for more than eight weeks. It is a common clinical problem that significantly impairs patients' physical, psychological, and social quality of life. Chronic cough remains a diagnostic and therapeutic challenge despite systematic evaluation and treatment of common etiologies such as asthma, gastroesophageal reflux disease",[25],"2026-04-19",{"date":118,"type":33},"2026-04-23",{"date":120,"type":33},"2026-03-10",{"date":122,"type":21},"2027-05-10",{"name":124,"class":40},"Assiut University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":131,"targetDuration":4,"studyType":54,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":75},"100621009","comprehensive-analysis-of-the-swallowing-mechanism-using-high-resolution-manometry-with-impedance-100621009","NCT07365046","Comprehensive Analysis of the Swallowing Mechanism Using High-resolution Manometry With Impedance","Inclusion Criteria:\n\n* age 18-75 years\n* patients with swallowing difficulties suspected of having a functional oesophageal disorder or patients with clinical signs of extra-oesophageal reflux (Reflux Symptom Index \\[RSI\\] ≥ 13 or Reflux Symptom Score-12 \\[RSS-12\\] ≥ 11) signed informed consent\n\nExclusion Criteria:\n\n* patients with a diagnosed tumor of the esophagus or upper airway, or with strong clinical suspicion of a tumor of the esophagus or upper airway\n* severe neurological disease affecting swallowing\n* pregnancy\n* surgery involving the head, neck, or esophagus within the last 6 months",{"count":132,"type":21},160,[88],"The aim of this project is to perform a detailed evaluation of upper esophageal sphincter function and the swallowing mechanism in patients with swallowing disorders or suspected extraesophageal reflux using high-resolution manometry with impedance and 24-hour pH-impedance monitoring.",[136,137,138,25],"Extraesophageal Reflux","Laryngopharyngeal Reflux","Dysphagia",[140,141,138,142,143,144],"Extraesophageal reflux","Laryngopharyngeal reflux","Chronic cough","high-resolution manometry","24-hour pH-impedance monitoring","2026-01-15",{"date":147,"type":33},"2026-01-23",{"date":149,"type":21},"2026-01",{"date":151,"type":21},"2028-12",{"name":153,"class":40},"University Hospital Ostrava",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":54,"phases":164,"briefSummary":166,"conditions":167,"keywords":172,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100615124","phase-4-a-2x2-factorial-randomized-open-label-trial-to-evaluate-neuromodulators-and-cough-control-therapy-in-patients-with-refractory-or-unexplained-chronic-cough-100615124","NCT07288528","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough (FORTITUDE)","FORTITUDE","Inclusion Criteria:\n\n1. Adults (≥18 years old) with either:\n2. Refractory chronic cough (RCC), defined as having one or more identifiable causes of cough (asthma, allergic rhinitis, and\u002For GERD), but with previous trials of treatment targeting the underlying condition leading to no cough resolution; OR\n3. Unexplained chronic cough (UCC), defined as having a cough lasting \\>8 weeks with (i) a normal chest X-ray\u002FCT in the last 5 years and since the onset of chronic cough; (ii) FEV1 and FVC ≥80% predicted or \\>lower limit of normal (LLN); (iii) FEV1\u002FFVC ≥0.7 or \\>LLN; (iv) no evidence of asthma; and (vi) no regular symptoms of nasal\u002Freflux disease.\n\nExclusion Criteria:\n\n1. Those who, in the opinion of the investigator, have previously tried low-dose morphine, pregabalin, and\u002For CCT with full intervention fidelity for the treatment of RCC\u002FUCC;\n2. Are currently taking morphine or pregabalin for the treatment of any indication (i.e., RCC\u002FUCC or chronic pain);\\*\n3. Are currently taking other centrally-acting medication (i.e., gabapentin, amitriptyline, dextromethorphan) for the treatment of any indication (i.e., RCC\u002FUCC, seizures, or depression);\\*\n4. Have a history of opioid or substance abuse that, in the opinion of the investigator, may interfere with the conduct of the study;\n5. Are a current smoker, or ex-smoker with a \\>20 pack-year history who have abstained from smoking for \\\u003C6 months;\n6. Have cough due to angiotensin-converting enzyme inhibitor use;\n7. Have symptoms of an upper respiratory infection within the last month that have not resolved;\n8. Had an asthma exacerbation within the last month that requires an increase or start of an oral corticosteroid;\n9. Have other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, interstitial lung disease, or severe bronchiectasis;\n10. Have language, memory, cognitive, or psychiatric issues that may prevent optimal participation;\n11. Have creatinine clearance \\\u003C15 mL\u002Fmin, including individuals with end-stage renal disease who require hemodialysis or peritoneal dialysis;\n12. Have any other condition that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n13. Have participated in another clinical trial of an investigational medicinal product within 30 days;\n14. Pregnant or breastfeeding; or\n15. Females of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months.\n    2. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.\n    3. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening.\n\n       * Participants taking any of the above medications at baseline will only be eligible if they are willing and medically able to safely discontinue them at least 2 weeks prior to the first study visit. Eligibility will be confirmed by the local study investigator prior to enrolment.",{"count":163,"type":21},124,[165],"PHASE4","The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.",[168,169,170,171,25],"Cough","Refractory Chronic Cough","Unexplained Chronic Cough","Cough Hypersensitivity Syndrome",[168,25,173,174,175,169,170],"Morphine","Pregabalin","Non-Pharmacologic Therapy","2025-12-04",{"date":178,"type":33},"2025-12-17",{"date":180,"type":21},"2026-04-01",{"date":182,"type":21},"2029-07-01",{"name":184,"class":40},"McMaster University",5,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100610820","biomarkers-and-respiratory-omics-as-new-children-opportunities---study-of-clinical-outcomes-and-predictivity-evaluation-100610820","NCT07232550","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation - a Multi-cohort, Multi-center Study","BRONCHOSCOPE","Inclusion Criteria:\n\n* Age at the beginning of the study 0-17 years old\n* Clinical indication and qualification by the attending physician for fiberoptic bronchoscopy under general anesthesia:\n\n  * Obstruction of the airways:\n  * Suspicion of foreign body aspiration\n  * Persistent stridor\n  * Abnormal result of functional tests of respiratory system - flattening of inspiratory or expiratory curve, presence of restriction (tested vital capacity \\\u003C5 percentile) or irreversible obstruction (persistence of Tiffneau index \\\u003C5 percentile despite administration of bronchodilators)\n  * Radiological findings located in the course of the larynx, trachea or bronchi\n  * Persistent atelectasis on subsequent radiological examinations\n  * Persistent cough \\>4 weeks\n  * Hemoptysis\n  * Suspected laryngomalacia or tracheobronchomalacia\n  * Suspected tracheoesophageal fistula\n  * Persistent dyspnea unresponsive to anti-asthmatic treatment used for min. 2 months, with no other identifiable causes\n  * Radiologically detected mediastinal abnormalities\n  * Suspected presence of a vascular ring\n  * Presence of excessive secretions that are impossible for the patient to expectorate\n  * Fine needle biopsy of cystic lesions\n* Obtained consent from patient\u002Flegal guardian for participation in the study\n\nExclusion Criteria:\n\n* Active acute respiratory infection up to 4 weeks before the procedure\n* Taking antibiotics or systemic glucocorticosteroids up to 4 weeks before the procedure\n* Patients with very severe comorbidities (congenital immunodeficiencies, genetic disorders, neurological or neuromuscular diseases, cancer, severe congenital heart defects, heart failure, liver failure, inflammatory bowel disease, celiac disease)\n* Patients with blood clotting disorders\n* Children with diagnosed respiratory diseases other than asthma and protracted bacterial bronchitis - including interstitial diseases, tuberculosis, inflammation of small and medium-sized blood vessels\n* Patients for whom \\>48 hours have passed between suspicion of foreign body aspiration and interventional bronchoscopy\n* Children with foreign body aspiration having a foreign body located in the trachea","17 Years",{"count":132,"type":21},"The goal of this observational study is to improve the identification of biomarkers that predict disease progression and to assess the effectiveness of current therapies in children with asthma and protracted bacterial bronchitis.\n\nThe main aim of the study is to evaluate the microbiome composition and diversity, cellular composition, and metabolomic profile. In addition, to assess their correlation on subsequent treatment and disease course in children with asthma, protracted bacterial bronchitis, and in those receiving inhaled glucocorticosteroids without a diagnosis of asthma.\n\nParticipants will undergo fiberoptic bronchoscopy. During bronchoscopy, the performing physician will collect Bronchoalveolar lavage fluid samples for metagenomic and metabolomic analysis, as well as mucosal biopsies for histopathological evaluation.",[198,199,25],"Asthma in Children","Protracted Bacterial Bronchitis",[201,202],"PBB","Asthma","2025-11-14",{"date":205,"type":33},"2025-11-18",{"date":207,"type":21},"2025-11",{"date":209,"type":21},"2035-12",{"name":39,"class":40},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":142,"eligibilityCriteria":217,"healthyVolunteers":218,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":54,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100607600","a-prospective-randomized-double-blind-study-on-the-effects-of-different-anesthesia-strategies-on-postoperative-cough-in-patients-undergoing-video-assisted-thoracoscopic-surgery-100607600","NCT07190664","A Prospective, Randomized, Double-blind Study on the Effects of Different Anesthesia Strategies on Postoperative Cough in Patients Undergoing Video-assisted Thoracoscopic Surgery.","A Prospective, Randomized, Double-blind Study of Different Anesthesia Strategies for Postoperative Cough in Patients Undergoing Video-assisted Thoracoscopic Surgery","Inclusion Criteria:\n\n1. planned wedge resection, segmentectomy or lobectomy;\n2. more than 18 years old;\n3. American Society of Anesthesiologists (ASA) grade ≤Ⅲ;\n4. body mass index (BMI) ≤24 kg\u002Fm2;\n5. Normal pulmonary function, predicted forced expiratory volume in 1 second (FEV1%) \\>50%, resting blood gas analysis showed arterial partial pressure of oxygen (PaO2) ≥75 mmHg and arterial partial pressure of carbon dioxide (PaCO2) \\\u003C45 MMHG;\n6. Normal cardiac function with ejection fraction (EF) \\> 50% of predicted value;\n7. Informed consent and signed informed consent form.\n\nExclusion Criteria:\n\n* (1) patients who refuse surgery and\u002For anesthesia; (2) preoperative pulmonary infection; (3) previous history of ipsilateral surgery or other medical history that may cause extensive pleural adhesions; (4) phrenic nerve palsy on the non-operative side; (5) patients with high risk of preoperative reflux (fasting \\\u003C6 hours) or gastroesophageal reflux disease; (6) patients with heart, kidney, liver and other organ dysfunction and surgical contraindications; (7) with severe cognitive, psychological and communication disorders.",true,{"count":220,"type":21},228,[88],"This study aims to systematically evaluate the effects of different anesthesia methods on postoperative chronic cough in lung cancer patients undergoing video-assisted thoracoscopic lung resection (VATS), and to clarify the effectiveness and safety of each anesthesia airway management strategy in reducing the incidence of postoperative chronic cough, shortening the duration of cough, alleviating the severity of symptoms, and improving the postoperative quality of life of patients.",[25,224],"Video-assisted Thoracoscopic Surgery (VATS)",[226,28],"Video-assisted thoracoscopic surgery","2025-09-17",{"date":229,"type":33},"2025-09-24",{"date":231,"type":21},"2025-10-01",{"date":233,"type":21},"2025-12-30",{"name":235,"class":40},"Fujian Medical University Union Hospital",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":75},"100545019","an-observational-study-using-novel-questionnaire-to-characterize-cough-phenotypes-in-patients-with-chronic-cough-100545019","NCT06376448","An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough","Inclusion Criteria:\n\n1. Male and female patients \\> 18yrs of age\n2. Patients with a current cough of at least 8 weeks duration\n3. Patients with a clear chest X-Ray within previous 2 yrs\n4. Non- smoker\n5. Able to understand and comply with the requirements of the study and sign Informed Consent forms.\n6. Good understanding of written and spoken English -\n\nExclusion Criteria:\n\n1. Recent respiratory tract infection (\\\u003C4 weeks prior).\n2. Current smokers or ex-smokers with \\\u003C6 months' abstinence prior to Study.\n3. Any clinically significant or unstable medical or psychiatric condition that would, in the opinion of the investigator, interfere with the subject's ability to participate in the study safely.\n4. Participation in any clinical research study evaluating an investigational drug or therapy within 30 days or within 5 half-lives (whichever is longer) of the investigational drug prior to Study visit. If the subject was in an observational clinical study no washout is required.\n5. Subjects who, in the opinion of the Investigator, should not participate in the study for any other reason.",{"count":243,"type":21},60,"Cough has previously been described by the type of cough you have ie such as wet, dry, and chesty, and also by its features such as how often you are coughing its,intensity, and severity, but never has the varying patterns of cough been studied in any detail and it could be that the pattern of the cough is closely related to patient-perceived intensity, frequency and most importantly severity. Cough is a symptom and like any other symptom (such as pain) the severity of it can only be gauged by the patient experiencing it.\n\nWe have created a one-page brand newl questionnaire that shows 4 distinct cough patterns that we believe exist and an empty field designed so that patients can record a pattern of cough they experience which is not already a choice on the questionnaire. The questionnaire also records patients' experience of how frequent, and intense, the cough is, and how it disrupts their lives, on a 1-10 scale (Visual analogue scale), the sum of these scores is collated and this gives us a severity score. The first phase of the project is to determine whether 30 Chronic cough patients understand the questionnaire, and are able to complete it with little direction, and if the cough patterns we identified encompassed all pattern types. second part of the study is to look at how repeatable the questionnaire is when completed over a 6 week period.",[25],"2025-07-29",{"date":248,"type":33},"2025-08-01",{"date":250,"type":33},"2022-10-24",{"date":252,"type":21},"2025-12-10",{"name":254,"class":255},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":218,"sex":16,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100538079","neuroinflammatory-interactions-of-atp-and-p2x3-receptor-in-the-airways-of-chronic-cough-patients-100538079","NCT06286163","Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients","Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients: an Exploratory Study","Inclusion Criteria:\n\n\\- 1. For Normal non-smoking subject: Healthy individuals, free of significant disease No history of asthma\u002Frhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1\u002FFVC ratio \\>70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years\n\n2\\. For chronic cough participants: History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months.\n\nUndergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough.\n\nWould have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found.\n\n3\\. General Inclusion Criteria: Give written informed consent prior to participation in the study including all of its procedures. Comply with the requirements and restrictions listed in the consent form.\n\nMale or female subject aged between 30 and 70 years old at screening. Able to complete the study and all measurements. Able to read, comprehend, and write at a sufficient level to complete study related materials.\n\nExclusion Criteria:\n\n\\-","30 Years","70 Years",{"count":266,"type":21},18,"This study is being done in order to understand what causes people to have a chronic cough, which is defined as a cough lasting for more than 8 weeks. The research team wish to find out whether there is any inflammation in the lungs of patients with chronic cough. The research team will also determine whether a suspected chemical produced in the body, called adenosine triphosphate (ATP) can be responsible for causing the chronic cough. In order to be able to find out what is abnormal in those who have a chronic cough, The research team will need to compare their results with those that do not have a chronic cough.\n\nIn this study, the research team will examine 10 participants who suffer from chronic cough and 8 individuals who do not have a chronic cough and are healthy.",[25],"2025-02-04",{"date":271,"type":33},"2025-02-07",{"date":273,"type":33},"2023-10-01",{"date":275,"type":21},"2025-12-31",{"name":277,"class":40},"Imperial College London",2,{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":54,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":278},"100557774","the-real-world-treatment-satisfaction-by-gefapixiant-in-rcc-100557774","NCT06542484","The Real-world Treatment Satisfaction by Gefapixiant in RCC","The Real-world Treatment Satisfaction by Gefapixiant in Patients with Refractory Chronic Cough in Terms of Cough Improvement and Taste Disturbance. (The RESTORE Study)","Inclusion Criteria:\n\n1. Adult patients with RCC and UCC (8 weeks or more).\n2. Cough is refractory to intensive specific treatments for causes of chronic cough.\n3. Never smokers and ex-smokers with having smoking history of ≤20 pack-years.\n\nExclusion Criteria:\n\n1. Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia.\n2. Current smoker, ex-smokers with having smoking history of \\>20 pack-years, or those who quit smoking within six months prior to receiving gefapixant.\n3. Those who are pregnant.",{"count":287,"type":21},63,[88],"Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.",[25],[25,292],"gefapixiant","2025-01-26",{"date":295,"type":33},"2025-01-29",{"date":297,"type":33},"2024-12-04",{"date":299,"type":21},"2026-06-30",{"name":301,"class":40},"Nagoya City University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":54,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":75},"100576253","chronic-cough-management-in-interstitial-lung-disease-100576253","NCT06782893","Chronic COUGH Management in Interstitial Lung DisEase","COUGH-LESS: Chronic COUGH Management in Interstitial Lung DisEase - Non-pharmacological Strategies and Solutions","COUGH-LESS","Inclusion Criteria:\n\ni) Adults (\\>18 years old) ii) Clinical diagnosis of ILD iii) Presenting chronic cough (\\> 8 weeks of duration) iv) People with access to a virtual meeting platform\u002Ftelephone.\n\nExclusion Criteria:\n\ni) Self-reports of moderate or large sputum production (\\> 2 tablespoons); ii) Actual or suspected exacerbation of the respiratory condition in the last month; iii) Upper respiratory tract infection (e.g. cold); iv) Use of angiotensin-converting enzyme inhibitor medication; v) Changes in prescribed medication in the last month; vi) Signs of cognitive impairment or significant cardiovascular, neurological and\u002For musculoskeletal disease that may limit participation in the program; vii) Inability to read or speak Portuguese; viii) Inability to provide informed consent.",{"count":243,"type":21},[88],"Interstitial Lung Disease (ILD) includes chronic, disabling and progressive respiratory conditions marked by lung inflammation and fibrosis. The quality of life and functionality of people with ILD is affected by a plethora of debilitating symptoms such as dyspnoea fatigue and cough. Among them, chronic cough (a cough lasting more than 8 weeks) reigns as one of the most prevalent and challenging, despite receiving far less attention from researchers than other symptoms. Chronic cough affects up to 8 out of 10 individuals with ILD and it is associated with a worse prognosis, mortality, and the need for lung transplantation. This condition showed a significant impact in people's life (e.g., urinary incontinence, speech interferences, depression, chest pain, couples sleeping in separate bedrooms, avoidance of public areas, reduced social interaction, and work absenteeism), further contributing to the decreased health-related quality of life experienced by this population. Managing chronic cough is, therefore, urgently needed. The general aim of this study is to explore the effects of a non-pharmacological cough control treatment on cough-related quality of life in people with ILD. The specific aims of this study are: i) to explore short- and mid-term effects of the non-pharmacological cough control treatment on cough related outcomes (e.g., cough frequency and intensity, dyspnoea, fatigue, cough self-efficacy, health-related quality of life and emotional status); ii) to identify (if any) adverse effects of this therapy.",[314,25],"Interstitial Lung Disease",[25,314,316],"Non-pharmacological cough control therapy","2025-01-14",{"date":319,"type":33},"2025-01-20",{"date":321,"type":21},"2027-12-20",{"date":323,"type":21},"2028-07-30",{"name":325,"class":40},"Aveiro University",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":54,"phases":336,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":75},"100501743","early-phase-1-effect-of-gefapixant-on-cough-related-brain-activity-in-patients-with-chronic-cough-100501743","NCT05813223","Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough","The Effect of Acute and Prolonged Administration of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough","Inclusion Criteria:\n\n* Written informed consent to participate in the study. 18-65 years old; Male or female.\n* Non-smokers for at least 5 years and have no history of neurological disease or any recent history (over 8 weeks) of acute respiratory infections.\n* Presence of Refractory Chronic Cough (RCC) or Unexplained Chronic Cough (UCC) for ≥1 year, defined as cough unresponsive to treatment for underlying conditions including reflux disease, asthma and rhinitis.\n* Presence of cough symptoms as determined by a self-reported cough severity of ≥40mm on 10-point scale on screening.\n\nExclusion Criteria:\n\n* Current smokers or recreational drug users.\n* Women who are pregnant.\n* People with contraindications to MRI scanning (i.e. metal implants, claustrophobia).\n* Children and\u002For young people (ie. \\\u003C18 years).\n* People with an intellectual or mental impairment.\n* People highly dependent on medical care.\n* People in existing dependent or unequal relationships with any member of the research team.\n* People with known allergy to chili (very rare).\n* Non-English speakers (as English proficiency is required to accurately complete research tasks).","65 Years",{"count":335,"type":21},31,[337],"EARLY_PHASE1","Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression in patients with chronic cough. The goal of this clinical trial is to investigate the effect of acute and prolonged administration of the drug Gefapixant on cough-related brain activity in patients with chronic cough. The main question it aims to answer is: does the mechanism of action of Gefapixant on the brainstem and brain circuits regulating cough differ between acute and prolonged therapy in people with chronic cough?\n\nParticipants have their brain activity and their sensitivity to cough-inducing substances measured as well as complete questionnaires about their cough before and while taking daily Gefapixant.",[25],[341,342,343,344,345],"functional brain imaging","ATP","Capsaicin","Refractory chronic cough","Mechanism of Disease","2024-05-07",{"date":348,"type":33},"2024-05-09",{"date":350,"type":33},"2024-01-01",{"date":299,"type":21},{"name":353,"class":40},"Stuart Mazzone"]